GoAI
Get started
Arbutus Biopharma Corp logo

Arbutus Biopharma Corp

ABUS

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$5.21

+$0.44 · +9.22%

Aug 21, 4:00 PM ET

ABUS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

87

Deep Value

Momentum

59

Neutral

Sentiment

54

Mixed

Risk resilience

67

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Lindsay Androski
Listed since
Jul 26, 2007
Employees
19

Market position

Day range

Current $5.21

52-week range

Current $5.21

Open
$5.20
Previous close
$4.77
Volume
18.07M
8.54× average
Average volume
2.12M
Average daily volume
Market cap
1.03B USD
Beta
0.6
Market reference 1
50-day average
$4.6068
+13.09% above average
200-day average
$4.4625
+16.75% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
6.59×
P/B (TTM)
3.98×
P/S (TTM)
5.66×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
99.98%
Operating margin
81.01%
Net margin
84.23%

Financial health

Debt / equity
0.01×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends234%-301%-836%-1370%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 97.42%Operating margin, FY2021: -669.11%Operating margin, FY2022: -167.75%Operating margin, FY2023: -430.53%Operating margin, FY2024: -1236.74%Operating margin, FY2025: -192.08%Net margin, FY2021: -693.91%Net margin, FY2022: -178.01%Net margin, FY2023: -401.57%Net margin, FY2024: -1133.04%Net margin, FY2025: -237.88%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 97.42%. Operating margin FY2021 -669.11%. Operating margin FY2022 -167.75%. Operating margin FY2023 -430.53%. Operating margin FY2024 -1236.74%. Operating margin FY2025 -192.08%. Net margin FY2021 -693.91%. Net margin FY2022 -178.01%. Net margin FY2023 -401.57%. Net margin FY2024 -1133.04%. Net margin FY2025 -237.88%.

Income trends

Revenue

14.08M USD+128.21%

Operating income

−27.05M USD+64.56%

Net income

−33.5M USD+52.09%
Income trends across reported periods50.73M USD3.88M USD−42.97M USD−89.82M USDRevenue, FY2021: 10.99M USDRevenue, FY2022: 39.02M USDRevenue, FY2023: 18.14M USDRevenue, FY2024: 6.17M USDRevenue, FY2025: 14.08M USDOperating income, FY2021: −73.52M USDOperating income, FY2022: −65.46M USDOperating income, FY2023: −78.1M USDOperating income, FY2024: −76.32M USDOperating income, FY2025: −27.05M USDNet income, FY2021: −76.25M USDNet income, FY2022: −69.46M USDNet income, FY2023: −72.85M USDNet income, FY2024: −69.92M USDNet income, FY2025: −33.5M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 10.99M USD. Revenue FY2022 39.02M USD. Revenue FY2023 18.14M USD. Revenue FY2024 6.17M USD. Revenue FY2025 14.08M USD. Operating income FY2021 −73.52M USD. Operating income FY2022 −65.46M USD. Operating income FY2023 −78.1M USD. Operating income FY2024 −76.32M USD. Operating income FY2025 −27.05M USD. Net income FY2021 −76.25M USD. Net income FY2022 −69.46M USD. Net income FY2023 −72.85M USD. Net income FY2024 −69.92M USD. Net income FY2025 −33.5M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue14.08M USD6.17M USD18.14M USD39.02M USD10.99M USD
Cost of goods sold363K USD————
Gross profit13.72M USD6.17M USD18.14M USD39.02M USD10.99M USD
Research and development25.24M USD54.04M USD73.7M USD84.41M USD65.5M USD
Selling, general, and administrative15.89M USD22.11M USD22.48M USD17.83M USD17.14M USD
Operating expenses40.77M USD82.49M USD96.24M USD104.48M USD84.51M USD
Interest income4.07M USD6.59M USD5.69M USD2.19M USD127K USD
Interest expense97K USD137K USD459K USD1.73M USD2.86M USD
Depreciation and amortization363K USD1.38M USD1.4M USD1.43M USD1.75M USD
Operating income−27.05M USD−76.32M USD−78.1M USD−65.46M USD−73.52M USD
Net income−33.5M USD−69.92M USD−72.85M USD−69.46M USD−76.25M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 3 misses, 3 met estimates
Average EPS surprise
+287.10%
11 comparable reports
Latest EPS result
-0.03
Estimate -0.02 · Miss by 50.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.950.560.18-0.21Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual -0.07, estimate -0.08, surprise +12.50%, Beat. Q2 2025, reported May 14, 2025: actual -0.13, estimate -0.09, surprise -44.44%, Miss. Q3 2025, reported Aug 6, 2025: actual 0.01, estimate -0.02, surprise +150.00%, Beat. Q4 2025, reported Nov 13, 2025: actual -0.04, estimate -0.056, surprise +28.57%, Beat. Q1 2026, reported Mar 23, 2026: actual -0.01, estimate -0.035, surprise +71.47%, Beat. Q2 2026, reported May 13, 2026: actual 0.87, estimate -0.03, surprise +3000.00%, Beat. Q3 2026, reported Aug 12, 2026: actual -0.03, estimate -0.02, surprise -50.00%, Miss. Q4 2026, reported Nov 16, 2026: actual —, estimate -0.023, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates193.41M129.09M64.77M449.65KQ1 '25MissQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual 1.57M USD, estimate 2.26M USD, surprise -30.26%, Miss. Q2 2025, reported May 14, 2025: actual 1.76M USD, estimate 2.24M USD, surprise -21.32%, Miss. Q3 2025, reported Aug 6, 2025: actual 10.74M USD, estimate 1.59M USD, surprise +574.98%, Beat. Q4 2025, reported Nov 13, 2025: actual 529K USD, estimate 841K USD, surprise -37.10%, Miss. Q1 2026, reported Mar 23, 2026: actual 1.05M USD, estimate 614.5K USD, surprise +71.03%, Beat. Q2 2026, reported May 13, 2026: actual 179.13M USD, estimate 750K USD, surprise +23783.47%, Beat. Q3 2026, reported Aug 12, 2026: actual 1.01M USD, estimate 700K USD, surprise +44.86%, Beat. Q4 2026, reported Nov 16, 2026: actual —, estimate 1M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$8.50

63.15% upside
Past 12 months12-month forecastHigh $8.50Average $8.50Low $8.50

Rating distribution

10 ratings
Strong buy00%
Buy880%
Hold220%
Sell00%
Strong sell00%

Recent analyst actions

4 institutions
JefferiesmaintainBuy

Corporate actions

Corporate action history

Stock split

Effective Nov 4, 2010

1:5

ABUS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ABUS

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
21.85M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
19.3M
Weight
0.02%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
18.4M
Weight
0.16%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
7.87M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
7.05M
Weight
0.05%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
5.65M
Weight
0.05%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
3.92M
Weight
0.02%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
3.62M
Weight
0.02%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%

Continue in GoAI

Research ABUS

research.disclaimer